MedTrace Logo

Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder

NCT02517424 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-03-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of vaporized cannabis in participants with chronic, treatment-resistant posttraumatic stress disorder.

Conditions

Interventions

DRUG

High THC/Low CBD Cannabis

Dried cannabis

DRUG

High THC/High CBD Cannabis

Dried cannabis

DRUG

Low THC/Low CBD Cannabis

Dried cannabis

Sponsors & Collaborators

  • University of British Columbia

    collaborator OTHER

  • Tilray

    lead INDUSTRY

Principal Investigators

  • Zach Walsh, PhD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-07
Primary Completion
2019-03-22
Completion
2019-03-22

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02517424 on ClinicalTrials.gov